Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Iams WT, Balbach ML, Phillips S, Sacher A, Bestvina C, Velcheti V, Wang X, Marmarelis ME, Sethakorn N, Leal T, Sackstein PE, Kim C, Robinson MA, Mehta K, Hsu R, Nieva J, Patil T, Camidge DR. Iams WT, et al. Among authors: velcheti v. Clin Lung Cancer. 2023 May;24(3):228-234. doi: 10.1016/j.cllc.2023.01.009. Epub 2023 Feb 8. Clin Lung Cancer. 2023. PMID: 36841727 Free PMC article.
To Crush or Not to Crush: Administering Dabrafenib and Trametinib Through a Nasogastric Tube in a Critically Ill Patient With Nonsmall Cell Lung Cancer - A Case Report and Review of Literature of Targeted Therapies Given Through Enteral Feeding Tubes.
Jang C, Lau SC, Velcheti V. Jang C, et al. Among authors: velcheti v. Clin Lung Cancer. 2024 May;25(3):e124-e128. doi: 10.1016/j.cllc.2023.12.013. Epub 2023 Dec 27. Clin Lung Cancer. 2024. PMID: 38185611 Free article. Review.
Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan.
Abu Hejleh T, AlSawalha K, Abdel Hafiz S, Al-Batsh T, Abu Hejleh R, Yaser S, Abu Jazar H, Khader J, Alnsour A, Mohamad I, Abdel Jalil R, Abu-Shanab A, Gharaibeh A, Abu Shattal M, Alibraheem A, Haddad H, Mahmoud N, Obeidat S, Al-Jaghbeer MJ, Furqan M, Cortellini A, Velcheti V, Al-Rabi K. Abu Hejleh T, et al. Among authors: velcheti v. Front Oncol. 2024 Apr 30;14:1369126. doi: 10.3389/fonc.2024.1369126. eCollection 2024. Front Oncol. 2024. PMID: 38746680 Free PMC article.
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, Hong DS, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W, Skoulidis F, Li BT. Dy GK, et al. Among authors: velcheti v. J Clin Oncol. 2023 Jun 20;41(18):3311-3317. doi: 10.1200/JCO.22.02524. Epub 2023 Apr 25. J Clin Oncol. 2023. PMID: 37098232 Free PMC article.
Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT).
Gridelli C, Peters S, Velcheti V, Attili I, de Marinis F. Gridelli C, et al. Among authors: velcheti v. ESMO Open. 2023 Apr;8(2):101192. doi: 10.1016/j.esmoop.2023.101192. Epub 2023 Mar 23. ESMO Open. 2023. PMID: 36965261 Free PMC article. Review.
[No title available]
[No authors listed] [No authors listed] PMID: 38010044
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.
Pan Y, Hao Y, Han H, Chen T, Ding H, Labbe KE, Shum E, Guidry K, Hu H, Sherman F, Geng K, Stephens J, Chafitz A, Tang S, Huang HY, Peng C, Almonte C, Lopes JE, Losey HC, Winquist RJ, Velcheti V, Zhang H, Wong KK. Pan Y, et al. Among authors: velcheti v. J Immunother Cancer. 2022 Sep;10(9):e004913. doi: 10.1136/jitc-2022-004913. J Immunother Cancer. 2022. PMID: 36472839 Free PMC article.
164 results